Cited 0 times in
Unresolved issues of immune tolerance in chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2021-05-21T16:49:43Z | - |
dc.date.available | 2021-05-21T16:49:43Z | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 0944-1174 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182579 | - |
dc.description.abstract | During the natural course of chronic hepatitis B virus infection, immune-tolerant phase is characterized by high viral replication, the presence of HBV e antigen (HBeAg), and normal or minimally elevated serum alanine aminotransferase. Immune-tolerant phase is usually regarded as a benign course of the disease. International guidelines recommend observation rather than treatment during immune-tolerant phase. In this article, we review unresolved issues related to the definition of true immune-tolerant phase and the benefit of antiviral treatment. Defining true immune-tolerant phase requires a careful approach and long-term follow-up. In previous studies, many patients were misclassified as being immune-tolerant phase. Noninvasive methods of assessing fibrosis are warranted for patients in the immune-tolerant phase. Yet, there has been controversy over the benefit and harm of antiviral treatment for immune-tolerant phase patients. Thus, further larger scale studies are needed to investigate the prognosis of patients in true immune-tolerant phase and their need for antiviral therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Springer International | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Unresolved issues of immune tolerance in chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Henry Lik-Yuen Chan | - |
dc.identifier.doi | 10.1007/s00535-020-01665-z | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J01416 | - |
dc.identifier.eissn | 1435-5922 | - |
dc.identifier.pmid | 32016713 | - |
dc.subject.keyword | Antiviral therapy | - |
dc.subject.keyword | Hepatitis B virus | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Immune tolerance | - |
dc.subject.keyword | Tenofovir | - |
dc.contributor.alternativeName | Lee, Hye Won | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 55 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 383 | - |
dc.citation.endPage | 389 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY, Vol.55(4) : 383-389, 2020-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.